Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association ... Nektar Therapeutics, BionTech Advisory Board: Amgen, Astella ...

Positive preliminary data from SEACRAFT-1, which we reported at the 36 th EORTC-NCI-AACR (ENA) Symposium last month, has refined our clinical development focus of naporafenib plus trametinib on ...

Data presented at SITC follows the Company's presentation at the 36 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024. The presentation at SITC titled, 'Phase 1 ...

Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being ...

Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...

BioNTech's Q3 revenue rose to €1.244 billion ($1.36 billion), driven by earlier COVID-19 vaccine approvals. Q3 net profit climbed to €198.1 million, with EPS increasing to 81 cents from 66 ...

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...

Molecular Targets and Cancer Therapeutics Symposium ("EORTC-NCI-AACR") to be held from October 23-25, 2024 in Barcelona, Spain. SKY-1214 is an oral RNA splicing modulator developed through the ...